Theuretzbacher, Ursula http://orcid.org/0000-0003-2116-7128
Bush, Karen http://orcid.org/0000-0002-7843-2474
Harbarth, Stephan
Paul, Mical
Rex, John H. http://orcid.org/0000-0003-3265-5872
Tacconelli, Evelina
Thwaites, Guy E.
Article History
Accepted: 12 February 2020
First Online: 9 March 2020
Competing interests
: U.T., M.P., E.T., and G.E.T. declare no financial relationships with any organizations that might have an interest in the submitted work. K.B. receives retirement compensation from Bristol-Myers Squibb, Johnson & Johnson and Pfizer, and is a shareholder in Entasis, Fedora and Johnson & Johnson. In the past year, she has served as a consultant or scientific advisory board member for Allecra, Entasis, Fedora, Forma, Gladius, Mutabilis and VenatoRx. J.H.R. reports holding positions as Chief Medical Officer & Director at F2G, Non-Executive Director and Consultant at Adenium Biotech, Operating Partner and Consultant at Advent Life Sciences and Expert-in-Residence at the Wellcome Trust, as well as being a member of the scientific advisory boards of Macrolide Pharmaceuticals, Bugworks Research, Basilea Pharmaceutica, Forge Therapeutics and Novo Holdings. He reports personal fees from Phico Therapeutics, ABAC Therapeutics, Polyphor, Heptares Therapeutics, Gangagen, Meiji Seika Pharma, Basilea Pharmaceutica International, Allecra Therapeutics, Forge Therapeutics, SinSa Labs, AtoxBio, Peptilogics, F. Hoffmann-LaRoche and Novo Holdings; he is a shareholder in AstraZeneca, F2G, Adenium Biotech, Advent Life Sciences, Macrolide Pharmaceuticals and Bugworks Research. S.H. reports receiving grants from IMI Brussels during the conduct of the present study, as well as grants from Pfizer, personal fees from Novartis, personal fees from DNA Electronics, personal fees from Bayer and personal fees from GSK outside the submitted work.